Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | TNF | P01375 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.40 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30074833 | 0.88 | PTGES (0.49) | EGFRPTGESMAPTLMNA | |
| SCHEMBL202476 | 0.88 | PTGES (0.49) | EGFRPTGESMAPTLMNA | |
| SCHEMBL29742161 | 0.84 | TSHR (0.47) | MEN1KMT2AMAPTPOLBMAPK1 | |
| SCHEMBL405386 | 0.84 | TSHR (0.47) | MEN1KMT2AMAPTPOLBMAPK1 | |
| SCHEMBL27747270 | 0.83 | PARP1 (0.50) | EGFRMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL28468025 | 0.83 | EGFR (0.42) | EGFRPTGESMEN1KMT2AMAPT | |
| SCHEMBL1024702 | 0.82 | MAPT (0.47) | MEN1KMT2AMAPTHTTALDH1A1 | |
| SCHEMBL358629 | 0.82 | MAPT (0.45) | EGFRPTGESMEN1KMT2AMAPT | |
| SCHEMBL1557518 | 0.82 | LMNA (0.41) | EGFRPTGESMEN1KMT2AMAPT | |
| SCHEMBL28027642 | 0.82 | MEN1 (0.38) | MEN1KMT2AMAPTHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 295 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107952425-B | Preparation method of antitumor drug NVP-BEZ235 intermediate | 四川协力制药股份有限公司 | 2020-05-08 | — | — | CN | claimed |
| US-12544448-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250270209-A1 | LRRK2 INHIBITORS | INTERLINE THERAPEUTICS, INC. | 2025-08-28 | — | — | US | disclosed |
| EP-3526220-B1 | COMPOUNDS AND METHOD FOR BLOCKING TRANSMISSION OF MALARIAL PARASITE | US HEALTH (US) | 2025-06-11 | — | — | EP | disclosed |
| US-20250108117-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-04-03 | — | — | US | disclosed |
| CN-119661531-A | Imidazolone compound as well as preparation method and application thereof | 北京富龙康泰生物技术有限公司 | 2025-03-21 | — | — | CN | disclosed |
| EP-4522616-A1 | LRRK2 INHIBITORS | Interline Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-119403801-A | LRRK2 inhibitors | 因特来治疗公司 | 2025-02-07 | — | — | CN | disclosed |
| US-12187746-B2 | C26-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2025-01-07 | — | — | US | disclosed |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | XRAD THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-1689747-A1 | 1H-IMIDAZO [4,5-C] QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2006-08-16 | — | — | EP | disclosed |
| US-7091214-B2 | Aryl substituted Imidazoquinolines | 3M INNOVATIVE PROPERTIES CO. (US) | 2006-08-15 | — | — | US | disclosed |
| EP-1687305-A1 | 1H-IMIDAZOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Novartis AG (CH) | 2006-08-09 | — | — | EP | disclosed |
| US-20060111387-A1 | ARYL SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY | 2006-05-25 | — | — | US | disclosed |
| CN-1747953-A | Aryl / hetaryl substituted imidazoquinolines. | 3M INNOVATIVE PROPERTIES CO (US) | 2006-03-15 | — | — | CN | disclosed |
| EP-1590348-A1 | ARYL / HETARYL SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2005-11-02 | — | — | EP | disclosed |
| WO-2005054237-A1 | 1H-IMIDAZOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2005-06-16 | — | — | WO | disclosed |
| WO-2005054238-A1 | 1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2005-06-16 | — | — | WO | disclosed |
| US-20040147543-A1 | Aryl substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-07-29 | — | — | US | disclosed |
| WO-2004058759-A1 | ARYL / HETARYL SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250108117-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | MTOR, RICTOR, RPTOR | EGFR 828/4885PTGES 3950/4885MEN1 369/4885 |
| US-12187746-B2 | C26-linked rapamycin analogs as mTOR inhibitors | MTOR, RICTOR, RPTOR | EGFR 759/4885PTGES 3532/4885MEN1 744/4885 |
| US-20250270209-A1 | LRRK2 INHIBITORS | LRRK2, PARK7, PINK1 | EGFR 2110/4885PTGES 2394/4885MEN1 2410/4885 |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | ATM, CHEK2, CHEK1 | EGFR 927/4885PTGES 3925/4885MEN1 2696/4885 |
| US-20040147543-A1 | Aryl substituted imidazoquinolines | IL2, IFNG, IRF3 | EGFR 3216/4885PTGES 296/4885MEN1 4521/4885 |
| US-12544448-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | RICTOR, MTOR, MLST8 | EGFR 2346/4885PTGES 4093/4885MEN1 380/4885 |
| US-20060111387-A1 | ARYL SUBSTITUTED IMIDAZOQUINOLINES | IL2, IFNG, IRF3 | EGFR 3216/4885PTGES 296/4885MEN1 4521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.